…
Medibank Private Limited provides private health insurance in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers members with health cover for hospital treatments; and ancillary cover, which provides members with health cover for healthcare services comprising dental, optical, and physiotherapy, as well as offers health insurance products to overseas visitors and students. The Medibank Health segment provides health management and in-home care services, as well as a range of telehealth and primary care services to government and corporate customers; and distributes travel, life, and pet insurance products; It underwrites and distributes private health insurance policies under the Medibank and ahm brands for resident and nonresident customers, broader community with wellbeing, prevention, primary care and homecare, with investments in short stay surgical and mental health facilities. The company was founded in 1976 and is based in Docklands, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Medibank Private Ltd is one of Australia's largest private health insurers, providing retail health insurance and related services to individuals and employers. Long-term growth drivers include demographic ageing, rising healthcare spending and potential expansion of digital and value-based care, which may support premium revenue and service diversification.
Key risks include regulatory changes to pricing and rebates, medical inflation and claims volatility, intense competition, and cyber and reputational exposures following past data breaches.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 927.90M | 728.80M | 711.70M | 727.10M | 560.00M |
| Minority interest | - | -8.50M | -3.90M | - | - |
| Net income | 638.70M | 500.80M | 492.50M | 511.10M | 393.90M |
| Selling general administrative | - | 1054.80M | 754.60M | 671.00M | 666.10M |
| Selling and marketing expenses | - | - | 172.20M | 115.50M | 85.90M |
| Gross profit | 1601.20M | 8556.30M | 8018.30M | 7499.30M | 7092.40M |
| Reconciled depreciation | - | 96.00M | 89.40M | 118.40M | 115.00M |
| Ebit | 943.70M | - | 717.10M | 608.70M | 445.00M |
| Ebitda | 1048.80M | 750.80M | 806.50M | 727.10M | 560.00M |
| Depreciation and amortization | 105.10M | - | 89.40M | 118.40M | 115.00M |
| Operating income | 927.90M | 7899.70M | 7001.00M | 608.70M | 445.00M |
| Other operating expenses | 8397.90M | 656.60M | 619.50M | 6772.20M | 6532.40M |
| Interest expense | 15.80M | 11.00M | 5.40M | 1.80M | 2.40M |
| Tax provision | - | 219.50M | 215.30M | 216.00M | 166.10M |
| Interest income | - | 144.40M | 131.40M | 3.20M | 17.90M |
| Net interest income | - | -11.00M | -5.40M | -1.80M | -2.40M |
| Income tax expense | 281.60M | 219.50M | 215.30M | 216.00M | 166.10M |
| Total revenue | 9325.80M | 8556.30M | 8018.30M | 7499.30M | 7092.40M |
| Total operating expenses | 673.30M | 656.60M | 1017.30M | 6766.00M | 6542.30M |
| Cost of revenue | 7724.60M | - | -8.10M | - | - |
| Total other income expense net | - | -7170.90M | -6289.30M | 174.30M | 248.30M |
| Net income from continuing ops | - | 509.30M | 496.40M | 511.10M | 393.90M |
| Net income applicable to common shares | - | 500.80M | 492.50M | 511.10M | 393.90M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 4752.90M | 4700.30M | 4685.40M | 4388.80M | 4552.80M |
| Intangible assets | 182.00M | 157.50M | - | 123.60M | 127.80M |
| Other current assets | - | - | 3778.70M | 42.70M | 2737.10M |
| Total liab | 2342.20M | 2364.20M | 2380.30M | 215.70M | 2607.20M |
| Total stockholder equity | 2430.70M | 2335.90M | 2305.70M | 2084.40M | 1945.60M |
| Other current liab | -39.10M | - | 85.10M | -215.70M | -241.40M |
| Common stock | 85.00M | - | 85.00M | 85.00M | 85.00M |
| Capital stock | - | 85.00M | - | 85.00M | 85.00M |
| Retained earnings | 2352.70M | 2223.50M | 2068.40M | 1971.50M | 1834.90M |
| Other liab | - | - | - | 177.30M | 120.50M |
| Good will | 507.30M | 342.40M | 323.70M | 204.50M | 204.50M |
| Other assets | - | - | 0.00M | 3490.50M | 3452.50M |
| Cash | 570.40M | 648.60M | 691.00M | 420.60M | 596.70M |
| Cash and equivalents | - | - | - | 420.60M | 596.70M |
| Total current liabilities | - | - | 2000.30M | 215.70M | 241.40M |
| Current deferred revenue | - | - | 48.70M | - | - |
| Net debt | -296.50M | - | -472.70M | -420.60M | -596.70M |
| Short term debt | 39.10M | - | 66.60M | 0.00M | 0.00M |
| Short long term debt | - | 35.00M | - | - | - |
| Short long term debt total | 273.90M | - | 218.30M | - | - |
| Other stockholder equity | - | - | - | -2056.50M | -1919.90M |
| Property plant equipment | - | - | - | 70.50M | 88.40M |
| Total current assets | 570.40M | - | 3778.70M | 420.60M | 596.70M |
| Long term investments | - | 264.30M | - | 392.10M | 338.30M |
| Net tangible assets | - | - | - | 1756.30M | 1613.30M |
| Short term investments | - | 225.30M | 3048.20M | 274.50M | 234.60M |
| Net receivables | - | 66.40M | - | 248.10M | 225.40M |
| Inventory | - | - | - | - | -3197.10M |
| Accounts payable | - | 205.90M | 1799.90M | 215.70M | 241.40M |
| Accumulated other comprehensive income | -7.00M | - | 152.30M | 27.90M | 25.70M |
| Non currrent assets other | 154.80M | - | -2858.80M | -477.70M | -503.60M |
| Non current assets total | 4182.50M | - | 906.70M | 477.70M | 503.60M |
| Capital lease obligations | - | 174.00M | - | - | - |
| Long term debt total | - | - | - | 24.40M | 46.70M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | 110.50M | -110.80M | 58.50M | -602.70M |
| Change to liabilities | - | - | - | 99.20M | 14.50M |
| Total cashflows from investing activities | -120.80M | 110.50M | -110.80M | 58.50M | -623.60M |
| Net borrowings | - | - | -1.30M | -39.70M | -38.80M |
| Total cash from financing activities | -579.90M | -533.80M | -487.30M | -419.10M | -399.90M |
| Change to operating activities | - | - | - | -180.50M | 282.80M |
| Net income | 638.70M | 500.80M | 492.50M | 511.10M | 393.90M |
| Change in cash | -78.20M | -42.40M | 270.40M | -176.10M | -75.00M |
| Begin period cash flow | 648.60M | 691.00M | 420.60M | 596.70M | 671.70M |
| End period cash flow | 570.40M | 648.60M | 691.00M | 420.60M | 596.70M |
| Total cash from operating activities | 622.50M | 380.90M | 868.50M | 184.50M | 948.50M |
| Depreciation | 105.10M | 96.00M | 89.40M | 40.70M | 41.20M |
| Other cashflows from investing activities | 18.10M | 120.10M | 64.50M | 100.40M | 14.20M |
| Dividends paid | 509.50M | 473.70M | 426.90M | 374.50M | 358.00M |
| Change to account receivables | - | -20.80M | 9.90M | -22.00M | -11.10M |
| Sale purchase of stock | -10.70M | -6.40M | -7.50M | -4.90M | -3.10M |
| Other cashflows from financing activities | -60.60M | -6.90M | -51.60M | -39.70M | -38.80M |
| Change to netincome | - | - | - | -126.90M | 30.20M |
| Capital expenditures | 19.40M | 11.20M | 57.60M | 41.90M | 35.10M |
| Change in working capital | -145.70M | -64.30M | 330.20M | -22.00M | -11.10M |
| Stock based compensation | - | 8.50M | 3.30M | 6.70M | 5.90M |
| Other non cash items | 24.40M | -160.10M | -46.90M | -367.30M | 513.40M |
| Free cash flow | 603.10M | 369.70M | 810.90M | 142.60M | 913.40M |
Sector: Financial Services Industry: Insurance - Specialty
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| MPL Medibank Private Ltd |
0.06 1.17% |
5.21 | 22.39 | 18.98 | 1.53 | 5.82 | 1.48 |
| NHF NIB Holdings Ltd |
-0.01 0.15% |
6.76 | 17.82 | 15.43 | 0.87 | 2.85 | 0.87 |
| HLI Helia Group Ltd |
0.05 1.01% |
5.00 | 6.22 | 7.25 | 3.10 | 1.44 | 2.95 |
Medibank Private Limited provides private health insurance in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers members with health cover for hospital treatments; and ancillary cover, which provides members with health cover for healthcare services comprising dental, optical, and physiotherapy, as well as offers health insurance products to overseas visitors and students. The Medibank Health segment provides health management and in-home care services, as well as a range of telehealth and primary care services to government and corporate customers; and distributes travel, life, and pet insurance products; It underwrites and distributes private health insurance policies under the Medibank and ahm brands for resident and nonresident customers, broader community with wellbeing, prevention, primary care and homecare, with investments in short stay surgical and mental health facilities. The company was founded in 1976 and is based in Docklands, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. David Koczkar B.Com., BCom, MAICD, PGDipFinance | CEO, MD & Director | 1973 |
| Mr. Mark Rogers B.Sc., BEng (Hons), BSc | Group Exec. of CFO & Group Strategy | NA |
| Dr. Andrew Wilson FACHSE, FRANZCP, M.M., MBBS, MM | Group Exec. & CEO of Amplar Health | NA |
| Mr. Milosh Milisavljevic | Group Exec. of Customer Portfolios | NA |
| Mr. John Goodall B.Sc., BSc (Hons) | Group Exec. of Technology & Operations | NA |
| Mr. Peter Kopanidis | Sr. Exec. of Corp. Fin. | NA |
| Colette Campbell | Sr. Exec. of Investor Relations | NA |
| Ms. Mei Ramsay B.A., BA, L.L.B., L.L.M., LLB, LLM | Group Exec. of Legal, Governance & Compliance and Company Sec. | NA |
| Emily Ritchie | Sr. Exec. of External Affairs | NA |
| Ms. Kylie Bishop B.A., BA (Hons) Psy, MOrgPsych | Group Exec. of People, Culture & Sustainability | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.